Biotechnology News and Research

RSS

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

WSBI, University of Colorado sign licensing agreement for TCISM targets

Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

8 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

USF granted patent for cell transplantation procedure

The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

The University of Texas Health Science Center at Houston (UTHealth) announced that its Biotechnology Commercialization Center (BCC) has leased more than three-quarters of its available space to eight Texas-based startups in less than a year. The center's focus is to assist biotech entrepreneurs and small companies with the translation of discoveries into innovative health solutions.

8 Jul 2010

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.

8 Jul 2010

Affymetrix anticipates second-quarter total revenues in the range of $71-72 million

Affymetrix, Inc. today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company's previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.

8 Jul 2010

BioMimetic reports final study results comparing Augment Bone Graft to autograft in foot, ankle fusion surgery

BioMimetic Therapeutics will report today the final, one year results of its North American Pivotal Study comparing Augment Bone Graft to autograft in foot and ankle fusion surgery. The presentation of the data by Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital, will take place at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting.

8 Jul 2010

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

8 Jul 2010

Oramed Pharmaceuticals signs MSA with sanofi-aventis

Oramed Pharmaceuticals Inc., a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the USA.

8 Jul 2010

Patent issued for jellyfish protein for therapeutic application

Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.

7 Jul 2010

NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36

NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.

7 Jul 2010

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

International Stem Cell Corporation and Sankara Nethralaya, announced today commencement of a collaboration to develop ISCO's "CytoCor™" stem cell-derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. "This is one more step in ISCO's stated plan of building its portfolio of therapeutic agents through strategic alliances throughout the world," said Chairman, Ken Aldrich.

7 Jul 2010

Northwest Biotherapeutics raises $2.65M during second-quarter

Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.

7 Jul 2010

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

Applied BioCode, Inc. and Maxwell Sensors Inc. announced today that they have received a $2.8M three-year grant from the Recovery Act Limited Competition: National Institutes of Health (NIH), for the development of a high throughput diagnostic multiplex testing platform using their Barcoded Magnetic Beads (BMB) technology for various high value immunodiagnostics and molecular diagnostic tests.

7 Jul 2010

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Codex Alimentarius Commission provides new guidance to help improve food safety

The maximum amount of melamine allowed in powdered infant formula is 1 mg/kg and the amount of the chemical allowed in other foods and animal feed is 2.5 mg/kg, according to new rulings from the United Nations' food standards body, Codex Alimentarius Commission.

7 Jul 2010

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

Biotechnology News and Research

Fibrocell Science completes enrollment in azficel-T histology study

WSBI, University of Colorado sign licensing agreement for TCISM targets

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

USF granted patent for cell transplantation procedure

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Affymetrix anticipates second-quarter total revenues in the range of $71-72 million

BioMimetic reports final study results comparing Augment Bone Graft to autograft in foot, ankle fusion surgery

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Oramed Pharmaceuticals signs MSA with sanofi-aventis

Patent issued for jellyfish protein for therapeutic application

NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

Northwest Biotherapeutics raises $2.65M during second-quarter

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Codex Alimentarius Commission provides new guidance to help improve food safety

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News